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SUMMARY
Hepatitis C virus infection evolves progressively persisting in the majority of patients (85%). Most patients have high ALT
(alanine aminotransferase) levels and approximately 25% normal ALT. The latter are usually female and there is no association
between genotype and severity of hepatic lesion. Histologic analysis usually shows small lesion and absence or low amount of
fibrosis, despite cirrhosis having been reported. Aiming at assessing prevalence, demographic, genotypical and anatomopathological
characteristics in patients with normal ALT levels, we have carried out a study of 68 chronic hepatitis C patients between January
1997 and April 2000. There was a prevalence of 13.8% chronic hepatitis C patients with normal ALT levels, 45.6% of which were
male and 54.4% female, the mean age being 38 +/- 13 years. We found a predominance of genotype 1 in 84.7% of the patients,
genotype 2 in 6.8% and genotype 3 in 10.7%. In 52.9% of the cases liver biopsies revealed liver reaction, periportal activity score
0-1 was observed in 85.3% of the patients and score 2-4 was seen in 14.7%. Structural activity score 0-1 was seen in 73.5% of the
patients and score 2-4 in 26.5% of them. Periportal activity ≥ 2 and structural activity > 1 was seen in 29%, but steatosis was not
seen in 73.5%. Our results suggest the need to revisit for liver biopsy practice in patients with Chronic Hepatitis C and normal
transaminases.
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INTRODUCTION
In spite of new hepatitis C virus (HCV) infections having declined
in the last decade in most developed countries, chronic hepatitis C is
still a major public health concern.
An estimated 200 million people are currently chronically infected
with HCV25. 75% of these patients have elevated ALT levels and in 20
to 30% ALT levels are normal29. HCV has become one of the major
causes of elevated aminotransferases in asymptomatic patients.
Serum aminotransferases testing has been widely used as a marker
of liver disease activity, however, the literature has objected to this
finding, because liver biopsies carried out in patients with normal
transaminases show some degree of hepatic lesion, although, in most
cases, histopathology of the lesion is mild and progression to fibrosis
lower than in patients with elevated ALT, thus, denying the healthy
virus carrier paradigm3.
POYNARD et al.20 have studied liver fibrosis progression by
analyzing large series of previously untreated HCV patients, with a
defined date of contamination and an average annual liver fibrosis
progression rate calculated by means of a single liver biopsy specimen.
Poynard’s study originated a model suggesting a broad spectrum of
progression and defining three groups of patients with fibrosis: those
with slow progression fibrosis (cirrhosis over 50 years of age), moderate
fibrosis (cirrhosis at 20 to 50 years of age), or rapid progression fibrosis
(period of infection under 20 years).The literature shows that patients
with normal ALT can represent the relatively slow fibrosis progression
rate population12,13,16,19.
There are currently six identified HCV genotypes and at least 80
subtypes7. In 199428, the nomenclature was standardized classifying
HCV genotypes. The six different genotypes and the, at least, 80
genotypes have proven to vary geographically. Genotypic diversity
affects numerous aspects of the disease for several reasons: in regard
to HCV epidemiology because it varies geographically and also because
determining the genotype is essential for studying the routes of
infection; in regard to HCV pathogenicity because HCV strains have
different levels of virulence, which may be responsible for co-infection
with multiple genotypes, in regard to HCV treatment because different
genotypes respond differently to medication.
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This study was carried out as part of a study protocol at the Medical
Investigation Laboratory for Hepatitis (LIM-47) aimed at studying HCV
and normal enzymes.
PATIENTS AND METHODS
Sixty-eight patients who were in accompaniment for chronic
hepatitis C at the viral hepatitis clinic at the Infectious and Parasitary
Diseases Department at the University of São Paulo School of Medicine
were studied from January 1, 1997 to April 30, 2000.
Inclusion criteria were positivity for anti-HCV serology
(immunoenzymatic method) by third and second generation ELISA,
RNA-HCV detection by qualitative and/or quantitative PCR methods,
a minimum of three normal (or 1.5-fold ULN) ALT levels over a 12-
month period and a representative liver tissue specimen for
histopathological analysis.
Routine biochemical tests were performed at the HC-FMUSP
Central Laboratory according to the manufacture’s standardized
procedures (Diagnostics Corporation, Indianapolis, U.S.A.).
Medical residents at the Parasitary and Infectious Diseases
Department carried out percutaneous liver biopsies preceded by
ultrasound. Specimens were fixed in a 10%-solution of formalin and
were subsequently stained with hematoxylin-eosin, Perls’, Mason’s
trichrome and reticulin. All biopsy specimens were examined by a
single pathologist according to the histopathologic and staging
classification system of the Brazilian Society of Pathology10.
Genotyping was carried out on stored samples at the Laboratory
for Hepatitis - LIM 47. 5’NC region was analyzed with PCR and
genotyping tests.
Genotyping HCV
TRUGENE HCV 5’NC genotyping kit: a 244-bp fragment from
the 5’NC of the HCV genome was amplified by RT-PCR using the
COBAS AMPLICOR Hepatitis C test (Roche Molecular Systems, Inc.,
Branchburg, N.J.). The amplified products were purified with the
QIAquick PCR purification kit (Quiagen, Inc., Valencia, CA) and
sequenced with the TRUGENE HCV 5’NC Genotyping Kit according
to the manufacturer instructions (Bayer Health Care Diagnostics,
Berkeley, CA, USA). All HCV sequences were analyzed with the
OpenGEne DNA sequencer and Gene Object sequence analysis software
(GL3.1.2)11.
Serotyping analysis
Serotypes were determined by the Murex HCV serotyping 1-6 assay.
This assay is used for the detection of type-specific NS4 derived
epitopes, presented as branched peptides in a microliter 96-well format.
Serotyping was performed according to the manufacturer’s instructions.
The results were scored as specific serotypes, multiple serotypes, no
type-specific antibodies or non-reactive, according to the interpretation
criteria established30.
The Ethics Committees at both the Infectious and Parasitary Diseases
Department and at the Hospital das Clinicas have approved this study.
DATA ANALYSIS
The proportion of patients with ALT serum levels less than or equal
to 1.5-fold ULN was calculated as a simple frequency, that is, the ratio
between the number of patients with normal ALT levels or with up to
1.5-fold ULN and the total number of patients that received assistance
at the clinic.
Considering the total number of patients chronically infected with
HCV with normal ALT or ALT up to 1.5-fold ULN, assisted at the
Viral Hepatitis Clinic at the Infectious Diseases and Parasitary
Department at HC-FMUSP, during the period of January 1, 1997 and
April 4, 2000 we calculated:
a. The distribution of patients according to gender, age group, presence
of steatosis, and genotype;
b. The distribution of patients according to liver tissue structural
alteration.
RESULTS
Prevalence of chronic hepatitis C and normal ALT (or 1.5 fold
ULN) levels found was of 68/492 or 13.82% (CI 95%: 10.90%;
17.19%), of which 31 (45.6%) were men and 37 (54.4%) women.
Patients’ age varied from 18 to 71 years of age, with mean age being
38 +/- 13 years.
According to Figure 1, 73.5% of the 68 patients presented periportal
activity score 0-1 and 26.5% of them periportal activity score 2-4. In
terms of structural activity, in 85.3% of the cases patients scored 0-1
and in 14.7%, 2-4.
Eighteen out of sixty-eight or 26.5% of the patients had liver
steatosis, of which 17 had mild steatosis and one moderate steatosis of
the liver. Of the total number of patients, 50 (73.5%) had no liver
steatosis at all.
Of 68 patients, 32 had chronic hepatitis. Of the latter, periportal
activity (PPA) 0 and structural activity (SA) 0 were seen in three
Fig. 1 - Distribution of patients with chronic hepatitis and normal ALT activity according
periportal and structural activities.
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patients; PPA 1 and SA 1, in eight; PPA 1 and SA 2, in two; PPA 1 and
SA 3, in one; PPA 2 and SA 1, in ten; PPA 2 and SA 2, in three, PPA 3
and SA 1, in one; PPA 3 and ASA 2, in two. Cirrhosis was not seen in
any of the 32 patients.
Genotyping was carried out in 59 patients. 50 were genotype 1, of
which seven were genotype 1, 25 were subtype 1b, 17 subtype 1a, and
a mixed subtype 1a/1b was present in one patient. Four patients were
genotype 2, of which one was genotype 2 and three patients were
subtype 2b. Five patients were genotype 3a as shown in Table 1 below.
DISCUSSION
Prevalence of hepatitis C with normal ALT varies from 7.5% to
46%1,15,16,17,19,22. The 13.8% prevalence rate found is confirmed by the
literature. All patients with normal ALT and ALT 1.5-fold ULN were
included in this study and underwent liver biopsy. However, patients
with only one or two ALT measurements in a year were not included
and this probably contributed to a decreased prevalence rate.
The variation between the prevalence established in this study and
prevalence rates in the literature is due to the fact that only patients
with persistently normal ALT levels and patients with minimally raised
ALT were included, to the variation in ALT levels obtained and to the
lack of data on alcohol intake.
Therefore, this study included patients with normal ALT and
patients with ALT not exceeding 1.5-fold ULN. Patients were selected
according to the criteria in PUOTI et al., which classify patients in
two groups: the biochemically silent, with persistently normal ALT
levels, and patients with minimally raise ALT18. 54.4% were women
and 45.6% were men, although several studies indicate the prevalence
of women in this population24,26,27, this possibly suggests a protective
effect of estrogens, which block the proliferation of stellate cells and
fibrogenesis21. Another possibility is that, histologically, due to the
different living styles adopted by men and women, especially
concerning alcohol intake, which is a well-known factor in the
pathological evolution process, the disease could be milder in women21.
Patients’ age varied between 18 and 71 years of age, being the
mean age 38 +/- 13 years, which corresponds to the expected age
according to ALTER et al.2 and FOCCACIA et al.8.
In regard to HCV genotypes, we found a prevalence of genotype 1
in 84.8% of the patients, followed by genotype 3 in 8.5% and by
genotype 2 in 6.7%. These findings are similar to the findings in
CAVALHEIRO et al.6  and BASSIT et al.3, who, in turn, do not determine
ALT levels.
Genotype distribution found here is similar to that of Europe where
there is also a prevalence of genotypes 1 and 3, and where dissemination
probably occurred by means of blood transfusion.
PUOTI et al. compared a group of patients with elevated ALT and
a group of patients with normal ALT and did not find an association in
either group between HCV genotype and degree of liver lesion24. This
argument can be used against the predictive value of genotype.
Among the histological characteristics, steatosis has appeared as
a fibrosis progression factor and is a common finding in chronic
hepatitis C.
Serotyping for characterizing HCV type by immunoenzymatic
method (ELISA) was performed in nine patients, because, although in
at least one moment, these patients tested positive for RNA-HCV with
PCR, in the samples examined retrospectively only results negatives
for HCV were available.
Previous studies have also highlighted aspects of the relation between
steatosis and HCV. Among said aspects, we can find high BMI and high
levels of triglycerides14. In this study, information on BMI, triglyceride
and glucose levels were not available in view of the fact that this is a
retrospective study, and characteristics such as weight, height, triglyceride
levels, were not always recorded on the patients’ charts.
Cross-sectional studies indicate that liver steatosis may be a
consequence of a cytopathic effect of hepatitis C virus, specially in
patients infected with genotype 3. Steatosis is seen in approximately
30 to 70% of hepatitis C patients14.
In this study, steatosis was seen in 26.5% of the patients, of which
only one had grade 2 steatosis; steatosis was not seen in 73.5%; and
10.5% were infected with genotype 3. These factors lead us to the
hypothesis that fibrosis evolves at a lower rate in this population.
According to previous research, the data in this study show that
the presence of HCV RNA is associated to the lesion, despite normal
ALT activity. This suggests that the determination of chronic hepatitis,
which is currently based on abnormal liver biochemical testing, should
be reexamined since liver lesions are usually found in patients with
normal ALT. Of 68 patients, in 52.9% of the cases biopsies showed
liver reaction (reactional liver), which, according to the Brazilian
Society of Pathology, reveals relatively smaller lesions than those
considered to be hepatitis, but, even so, these lesions are not within
the normality rates, because of the minimal aggressive action of the
virus or of the nonspecific response of liver cells to other systemic
procedures10.
The spectrum of liver lesions found in patients with chronic hepatitis
C and normal ALT varies, but there is a general consensus in the literature
that, in most cases, histological lesions are mild. The data in this study
Table 1
Distribution of chronic hepatitis C patients and normal ALT activity
according to genotypes
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are similar to those described in the literature1,9,18,24 according to which,
although fibrosis takes place, it occurs less than in patients with elevated
ALT, possibly because of the correlation between intensity of
necroinflammatory activity and progression to fibrosis; so the histological
lesions are milder pursuant to a recent study by FONTAINE et al.9.
According to world consensus, mild to severe hepatitis and
compensated cirrhosis must be treated and the current criteria in effect
established by the Brazilian Health Ministry in 20024, stating that
patients with PPA > 2 and/or SA > 1, which corresponds to 29% of the
patients in this study, recommend antiviral treatment. ZEUZEM et
al.31 in 2004 concluded that the efficacy and safety of peginterferon
alfa-2a and ribavirin combination therapy in patients with chronic
hepatitis C and persistently normal ALT levels are similar to that in
patients with elevated ALT levels. The indication for treatment of
hepatitis C can be evaluated independently from baseline ALT activity.
This confirms that carrying out biopsies regardless of ALT levels, can
contribute to tranquilizing patients with small lesions (who constitute
the majority of the population), identifying severe liver lesions and
selecting patients for treatment.
RESUMO
Pacientes com hepatite C crônica e transaminases normais
Hepatite C é uma doença de evolução progressiva. A maioria dos
pacientes tem nível de ALT elevada e 25% apresentam níveis normais.
Os com ALT normal geralmente são do gênero feminino e sem
associação entre genótipo e gravidade de lesão hepática. O exame
histopatológico mostra geralmente ausência de ou leve fibrose (cerca
de 20% tem fibrose), embora cirrose já tenha sido relatada. Visando
estimar a prevalência, características demográficas, genotípicas e
anatomopatológicas em pacientes com ALT normal, realizamos um
estudo de série com 68 casos com diagnóstico de hepatite C crônica.
Os pacientes foram selecionados de janeiro de 1977 a abril de 2002.
Encontrou-se uma prevalência de 13,8% (45,6% masculinos). A média
de idade foi 39 +/- 13 anos. Predomínio de genótipo 1 (84,8%), seguido
pelo 3 (8,5%) e 2 (6,7%). Encontramos fígado reacional em 52,9% das
biópsias, atividade periportal de 0-1 em 85,3% e atividade periportal
de 2-4 em 14,7%. Apresentaram atividade estrutural de 0 a 1 73,5% e
26,5% com atividade estrutural de 2 a 4, sendo que 29% da amostra
apresentou APP ≥ 2 e AE > 1; 73,5% não apresentaram esteatose. Nossos
dados reforçam a necessidade de biópsia em pacientes com hepatite C
e níveis de ALT normais.
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